PF-Atlas › Clinical Trials › NCT02029521
Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients
Oral reduced l-glutathione · Not specified
Registry ID
NCT02029521
Phase
Not specified
Status
Completed
Drug / intervention
Oral reduced l-glutathione
Sponsor
Clark Bishop
Start
2011-03
Enrollment
47
Locations
1
About this trial
Many individuals with cystic fibrosis experience growth failure. The reasons are not clear, but inflammation of the gut in these patients seems to be one important reason. Glutathione is important to normal function of the intestine and lungs. Glutathione functions to decrease inflammation and to thin mucus. However, in cystic fibrosis, glutathione gets trapped inside of cells, so it cannot travel to the surface of the cells and perform its proper function. Moreover, glutathione has been shown to improve nutritional status in patients with AIDS and cancer. Investigators hypothesize that supplementation of oral glutathione to pediatric individuals with cystic fibrosis could improve growth failure.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02029521 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.